Amgen Inc.

The transcript does not explicitly mention any current or planned fundraising through debt or equity. However, relevant financial insights include: - Amgen acknowledges an intense capital market environment with increased flows into the sector. - The company emphasizes the importance of execution and capital allocation to growth areas like biosimilars and innovative medicines. - They express a commitment to growing volumes and after-tax cash flows while maintaining operating margins. - Amgen mentions flexibility in managing operating margins and the balance between internal investments and potential external opportunities. - No direct statements about issuing new debt or equity were made during the call.

- Amgen plans to increase R&D investment in 2021, focusing on promising mid-stage pipeline candidates. - The company is investing in building differentiated capabilities in human genetics and large-scale proteomics to aid drug discovery and clinical trial design. - Strategic investment is being made in the induced proximity platform (formerly called targeted protein degradation), expanding druggable targets beyond proteins. - Amgen is investing in digitization and automation to improve operating productivity and maintain operating margin flexibility. - Continued allocation of capital to the biosimilars franchise, leveraging strong execution and competitive margins. - The company is pushing global expansions, including increased field force investments in Japan, China, Russia, and other emerging markets. - Committed to ambitious ESG goals, including achieving carbon neutrality by 2027 and reducing waste as part of strategic environmental investments.

- Amgen expects continued volume growth in key products such as Prolia, Otezla, Repatha, and EVENITY, supporting 2021 revenue guidance of $25.8 to $26.6 billion. - Continued international expansion, including reimbursement for Prolia in Japan and launches planned for Aimovig and biosimilars in multiple global markets. - Growth anticipated from the innovative oncology portfolio, including Sotorasib and Tezepelumab launches. - Biosimilars sales expected to grow in volume, partially offset by net price declines due to increased competition. - Price declines expected at mid-single digit globally, with operating margin guidance around 50% supported by cost discipline and digital efforts. - Otezla's growth is expected from both expansion in mild to moderate psoriasis indications and geographic expansion beyond the US. - New patient starts for products like Aimovig may recover post-COVID, supporting volume growth. - Overall, Amgen anticipates quarter-to-quarter variability due to COVID-19 but remains confident in volume-driven growth strategy.

- Amgen delivered 12% non-GAAP EPS growth year-over-year in 2020 with strong execution (Page 2). - 2021 non-GAAP earnings per share guidance is $12.12 to $13.17, reflecting continued growth (Page 2). - Revenue guidance for 2021 is $25.8 billion to $26.6 billion, with growth driven by volume increases in key products like Prolia, Otezla, Repatha, EVENITY, and innovative oncology portfolio (Page 2). - Operating expenses expected to grow ~7% in 2021 due to increased R&D and commercial investments, especially for pipeline candidates like Sotorasib and Tezepelumab (Page 2). - Operating margin expected to remain around 50% in 2021 with continued focus on cost efficiency and productivity (Page 2). - Mid-single digit net selling price declines anticipated due to competitive pressures (Page 2). - Long-term commitment to investing in innovation and maintaining strong financial discipline highlighted (Page 3).

The provided transcript does not contain specific information about Amgen’s current or expected orderbook or pending orders. The focus of the discussion is primarily on: - Product performance and sales growth (e.g., 15% volume growth, strong sales in 2020). - Pipeline updates including sotorasib and Tezepelumab regulatory submissions and trial progress. - Biosimilar portfolio and competitive landscape. - Early-stage R&D progress on human genetics and induced proximity platforms. - Commercial operations adjustments with digital engagement and sales force realignment. No explicit mention of orderbook values or pending orders figures is provided in the transcript excerpts.